Navigation Links
New cardiovascular score developed to improve heart attack and stroke detection
Date:6/24/2008

A new and more accurate method of assessing people at risk from cardiovascular disease (CVD) is set to improve national diagnosis rates and identify those at risk among black and minority ethnic groups.

QRisk2, an equation developed to help doctors identify those most at risk of developing CVD for the first time, simultaneously takes into account extra risk from ethnicity, social deprivation and other clinical conditions such as family history of heart disease or diabetes.

The study, to develop QRisk2, was undertaken by QResearch a not-for-profit partnership between The University of Nottingham and leading primary care systems supplier, EMIS.

Researchers from the Universities of Edinburgh and Queen Mary's and from Bristol and Medway Primary Care Trusts also supported the project.

Doctors will be able to use this information to help decide how best to target patients with preventative measures such as lifestyle advice and cholesterol-lowering treatments.

The research reveals that certain ethnic groups are at much greater risk than the general population, with men of Pakistani background being nearly twice as likely to suffer a heart attack or stroke. For Bangladeshi men, the risk increases by nearly 70 per cent.

The National Institute for Clinical Excellence (NICE) recommends that the Framingham equation, based on American data from a predominantly white population, be modified to take into account the increased risk in South Asian men. However, no adjustment is recommended for South Asian women.

QRisk2 identifies the risk of CVD in this portion of the population, indicating that in Indian, Pakistani and Bangladeshi women, the risk is 43 per cent, 80 per cent and 35 per cent higher, respectively, than in the background population.

Commenting on the research published on BMJ.com today, QRisk2 project leader, Professor Julia Hippisley-Cox of The University of Nottingham, said: "Based on the study of 15 years of data from over 2 million UK patients, QRisk2 is a contemporary and specific risk score that allows CVD risk to be personalised to the individual patient.

"Qrisk2 has been developed for GPs, by GPs and without the co-operation of the thousands of working GPs who freely contribute their data to QResearch, projects like QRisk2 could not happen."

Dr David Stables, Clinical Director of EMIS and a Director of Qresearch, said: "QRisk2 is likely to be a more efficient tool for treatment decisions, supporting the primary prevention of cardiovascular disease.

"We are currently working on software that will enable GPs to implement QRisk2 easily within clinical practice."

The study comes as the Government's health watchdog, NICE, recommends a systematic identification of people with a 20 per cent chance of developing heart disease in the next 10 years. The Government is investing an extra 500 million to support this work.


'/>"/>

Contact: Julia Hippisley-Cox
julia.hippisley-cox@nottingham.ac.uk
44-011-584-66915
University of Nottingham
Source:Eurekalert

Related medicine news :

1. American Heart Associations 3rd new journal -- Circulation: Cardiovascular Imaging
2. American Heart Associations Third New Journal - Circulation: Cardiovascular Imaging - Set for July Launch
3. Rheumatoid arthritis is a risk factor for cardiovascular disease
4. Rheumatoid arthritis factors equal to cardiovascular factors in risk of severe cardiovascular events
5. Primary snoring in children impacts cardiovascular functioning
6. Statement of Robert OConnor, M.D., M.P.H. Chair, American Heart Association, Emergency Cardiovascular Committee, on U.S. House of Representatives Passage of the Josh Miller HEARTS Act
7. Genomics of Cardiovascular Disease: Current Clinical Applications
8. Cardiovascular Meds May Be Beneficial in Alzheimers Disease, According to MedPredict Report
9. Study shows pine bark naturally reduces cardiovascular risk factors in diabetics
10. Study Shows Pine Bark Naturally Reduces Cardiovascular Risk Factors in Diabetics
11. American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... ... According to an article published February 4th on mySA, robotically ... hernia repairs throughout the United States. Commenting on this article, Beverly Hills hernia repair ... has not only been expected, but it seems to be a natural result of ...
(Date:2/12/2016)... ... ... Enforcement Trends: , Back to the Future , Feb. 25, 2016 — 11:00 a.m. – ... who don’t learn from history are doomed to repeat it.” , An analysis of CDRH’s ... But that takes time. , Take a close look at the warning letters the ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., ... have closed for the ISE Southeast Awards 2016. Finalists and winners of the ... ISE® Southeast Executive Forum and Awards Gala on March 15, 2016 at the ...
(Date:2/12/2016)... ... 12, 2016 , ... AssureVest Insurance Group, a locally owned insurance firm with ... will raise funds earmarked to purchase computers and software for Mrs. Harrison’s 2nd and ... is in a low-income area and has more than 60 2nd and 3rd graders ...
(Date:2/12/2016)... ... February 12, 2016 , ... Donor Network West, the organ procurement organization that ... partnership with San Ramon Regional Medical Center. Under the collaboration, the first of its ... to accommodate a more certain time frame for donor families for the recovery of ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  SI-BONE, Inc., a medical device company that pioneered ... minimally invasive surgical (MIS) device indicated for fusion for certain disorders ... (NGS), the Medicare Administrative Contractor (MAC) covering the states of ... Maine , Massachusetts , Minnesota ... York , Rhode Island , ...
(Date:2/12/2016)... SAN DIEGO and SEOUL, ... -- Silicon Biosys­tems Menarini and Macrogen, Inc. today ... clinical assays and innovative procedures for precision medicine ... to combine Silicon Biosystems, DEPArray™ digital-sorting technology with ... development of tests certified under the Clinical Laboratory ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
Breaking Medicine Technology: